Disease · MONDO_0000448

paraganglioma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. paraganglioma. Diseases, record MONDO_0000448. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0000448

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: paraganglioma; Open Targets
Open Targets ID: MONDO_0000448; Open Targets
Other names: Paraganglionic neoplasm, Paraganglionic tumor, Paraganglionic tumour, neoplasm of paraganglion, neoplasm of the paraganglion, paragangliomas, paraganglion neoplasm, paraganglion tumor, paraganglion tumour, tumor of paraganglion, tumor of the paraganglion, tumour of paraganglion, tumour of the paraganglion; Open Targets
Disease Ontology: DOID:0050773; Disease Ontology
MeSH: D010235; MeSH
NCI Thesaurus: C3308; NCI Thesaurus
Highest stage of its drugs: Approval, for 2 of its 65 drugs, from ClinicalTrials.gov and FDA; Open Targets

Drugs65

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
IOBENGUANE I 131	CHEMBL1615779	Small molecule	Approval	ClinicalTrials.gov and FDA	6	5	2	Drugs and targets
IOBENGUANE I 123	CHEMBL1615777	Small molecule	Approval	ClinicalTrials.gov	2	2	0	Drugs and targets
TEMOZOLOMIDE	CHEMBL810	Small molecule	Phase 3	ClinicalTrials.gov	12	12	12	Drugs and targets
DEXTROAMPHETAMINE SULFATE	CHEMBL3544971	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
PACLITAXEL	CHEMBL428647	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
SAFUSIDENIB	CHEMBL4651002	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
LUTETIUM OXODOTREOTIDE LU-177	CHEMBL4297545	Protein	Phase 2	ClinicalTrials.gov	6	6	3	Drugs and targets
BEVACIZUMAB	CHEMBL1201583	Antibody	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
IVOSIDENIB	CHEMBL3989958	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
NIVOLUMAB	CHEMBL2108738	Antibody	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets

1 to 10 of 65

See all 65 drugs

Targets147

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
KDR	Vascular endothelial growth factor receptor	9	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3791	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	7	Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2324	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	6	Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2321	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor	6	Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/5159	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	5	Stem cell growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3815	Drugs and targets
IDH1	IDH1/IDH2	4	IDH1/IDH2 inhibitor; Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor	Phase 3	https://conductscience.org/library/genes/3417	Drugs and targets
PDCD1	Programmed cell death protein 1	4	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 2	https://conductscience.org/library/genes/5133	Drugs and targets
PDGFRA	Platelet-derived growth factor receptor	4	Platelet-derived growth factor receptor alpha inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/5156	Drugs and targets
FGFR3	Fibroblast growth factor receptor	3	Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2261	Drugs and targets
FLT3	Receptor-type tyrosine-protein kinase FLT3	3	Tyrosine-protein kinase receptor FLT3 inhibitor	Phase 2	https://conductscience.org/library/genes/2322	Drugs and targets

1 to 10 of 147

See all 147 targets

Trials71

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 7 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02052648	Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors	Phase 1/2	160	2024-03-27	Glioblastoma Multiforme, Glioma, Gliosarcoma, Malignant Brain Tumor	INDOXIMOD, TEMOZOLOMIDE	Open Targets' reading of its record	ClinicalTrials.gov
NCT04400474	Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study	Phase 2	93	2025-06-19	Neuroendocrine Tumor, Anaplastic Thyroid Cancer, Adenocarcinoma, Pheochromocytoma, Paraganglioma	ATEZOLIZUMAB, CABOZANTINIB	Its record names the disease	ClinicalTrials.gov
NCT00404495	Combination of Irinotecan and Temozolomide in Children With Brain Tumors.	Phase 2	83	2012-02-17	Glioma, Medulloblastoma	IRINOTECAN, TEMOZOLOMIDE	Open Targets' reading of its record	ClinicalTrials.gov
NCT01986348	Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas	Phase 2	76	2021-08-02	Glioblastoma, Glioma	SELINEXOR	Open Targets' reading of its record	ClinicalTrials.gov
NCT04187404	A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma	Phase 1/2	70	2026-01-30	Adrenocortical Carcinoma, Pheochromocytoma, Paraganglioma	NIVOLUMAB, TIGOZERTINIB	Its record names the disease	ClinicalTrials.gov
NCT03718767	Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype	Phase 2	62	2025-11-24	Glioma, Glioblastoma, High Grade Glioma, Low Grade Glioma, Malignant Glioma	NIVOLUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT01118377	A Study of Capecitabine (Xeloda®) and Concomitant Radiation Therapy in Children With Newly Diagnosed Brainstem Gliomas	Phase 2	45	2013-12-03	Brainstem Glioma	CAPECITABINE	Open Targets' reading of its record	ClinicalTrials.gov
NCT00108069	Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors	Phase 2	43	2014-06-12	Glioma	BORTEZOMIB, TAMOXIFEN	Open Targets' reading of its record	ClinicalTrials.gov
NCT03687957	rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temozolomide	Phase 1/2	42	2025-11-25	Glioma	INTERLEUKIN-7	Open Targets' reading of its record	ClinicalTrials.gov
NCT00424554	Low-dose Temozolomide for 2 Weeks on Brain Tumor Enzyme in Patients With Gliomas (P04602 AM1) (Completed)	Phase 2	40	2011-06-29	Glioma	TEMOZOLOMIDE	Open Targets' reading of its record	ClinicalTrials.gov

1 to 10 of 71

See all 71 trials

Comparisons in its trials10

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Temozolomide + Irinotecan for Medulloblastoma vs Temozolomide + Irinotecan for High-Grade Glioma: serious adverse events	31 of 66	5 of 17	83	NCT00404495	Trial comparisons
GBM (Glioblastoma Multiforme) vs AG (Anaplastic Glioma): Number of Participants With Adverse Events	30 of 30	12 of 12	42	NCT00108069	Trial comparisons
GBM (Glioblastoma Multiforme) vs AG (Anaplastic Glioma): serious adverse events	11 of 30	3 of 12	42	NCT00108069	Trial comparisons
Temozolomide (TMZ) vs No Intervention: Tolerability: Number of Participants Discontinuing Treatment Due to Adverse Events (AE)	0 of 34	0 of 6	40	NCT00424554	Trial comparisons
Temozolomide vs No Intervention: serious adverse events	0 of 34	0 of 6	40	NCT00424554	Trial comparisons
Cohort 1/Hypermutated Phenotype (HMP) vs Cohort 2/Non-hypermutated Phenotype (NHMP).: Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)	7 of 8	26 of 30	38	NCT03718767	Trial comparisons
Cohort 1/Hypermutated Phenotype (HMP) vs Cohort 2/Non-hypermutated Phenotype (NHMP).: deaths from any cause	6 of 8	16 of 30	38	NCT03718767	Trial comparisons
Cohort 1/Hypermutated Phenotype (HMP) vs Cohort 2/Non-hypermutated Phenotype (NHMP).: serious adverse events	3 of 8	11 of 30	38	NCT03718767	Trial comparisons
GEP-NET vs PPGL: Incidence of Adverse Events (AEs) and Lab Toxicities After 1st Lutathera Administration	4 of 4	6 of 7	11	NCT04711135	Trial comparisons
Treatment: Pazopanib Without Run-in vs Treatment: Pazopanib With Run-in: serious adverse events	2 of 2	1 of 4	6	NCT01340794	Trial comparisons

Papers from its trials45

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41124218	RESULT	1	PubMed
37142373	RESULT	1	PubMed
35552677	RESULT	1	PubMed
33649582	RESULT	1	PubMed
33122995	RESULT	1	PubMed
32832670	RESULT	1	PubMed
32603316	RESULT	1	PubMed
32599393	RESULT	1	PubMed
32506369	RESULT	1	PubMed
32335153	RESULT	1	PubMed

1 to 10 of 45

See all 45 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0000448

GET https://conductscience.org/api/diseases/v1/MONDO_0000448/drugs?page=2

API reference For AI assistants